Comparative Pharmacology
Head-to-head clinical analysis: DASATINIB versus RETEVMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DASATINIB versus RETEVMO.
DASATINIB vs RETEVMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dasatinib is a tyrosine kinase inhibitor that targets BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. It inhibits BCR-ABL autophosphorylation and downstream signaling, leading to apoptosis in Philadelphia chromosome-positive (Ph+) leukemia cells.
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
140 mg orally once daily; reduce to 100 mg once daily if no cytogenetic response after 3 months or 140 mg once daily with dose escalation to 200 mg once daily as tolerated.
160 mg orally twice daily
None Documented
None Documented
Clinical Note
moderateDasatinib + Deslanoside
"Dasatinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDasatinib + Acetyldigitoxin
"Dasatinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateDasatinib + Ouabain
"Dasatinib may decrease the cardiotoxic activities of Ouabain."
Clinical Note
moderateDasatinib + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Dasatinib."
Terminal elimination half-life is 3-5 hours. This short half-life supports twice-daily dosing, but active metabolite (N-desmethyl dasatinib) has a similar half-life and contributes to PD activity.
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
Approximately 85% of the dose is eliminated via feces (mainly as metabolites), and about 4% via urine (parent drug and metabolites). Less than 1% is excreted unchanged in urine.
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor